Novel Antiviral Therapeutics for Treating Coronaviruses and Filoviruses☆
|AFFILIATION:||Phelix Therapeutics LLC, Philadelphia, Pennsylvania, United States|
Track: Medical & Biotech
Area: Infectious Disease
Tech Readiness: TRL 5
Tech Brief: Based on its unique knowhow of cathepsin biology and inhibition, Phelix has developed a platform technology that is yielding a portfolio of candidate antiviral therapeutics. Initial targets are viruses without approved treatment options including coronaviruses such as SARS/MERS, and filoviruses such as Ebola and Marburg.
Value Proposition: Coronavirus (SARS & MERS) and filovirus (including Ebola and Marburg)therapeutics will offer significant utility for DoD personnel deployed in at-risk regions,as well as a needed treatment for the US population in response to the high potential for person-to-person transmission and the inevitable spread to North America of their viral vectors. Led by the U.S. Agency for International Development,DoD response to Ebola outbreaks included ~2,400 personnel based in at-risk regions. Although not directly involved in treating Ebola patients, DoD personnel remain at high risk for contracting Ebola in their role of providing logistical support, training for health care workers, testing medical samples and constructing field treatment units. Contact among other DoD personnel, and subsequent spread to the US civilian population, is a major transmission risk. Ebola opinion leaders suggest that the virus could jump from sub-Saharan Africa to South/Central America,and then to N. America in the same pattern as Zika virus. Similar to Ebola, coronaviruses enter the population due to deforestation and incursion into previously undeveloped regions, with exacerbation due to global travel. The explosive emergence of coronavirus has led to programs in the US and other governments to stockpile less effective coronavirus therapeutics.
Org Type: Early-stage Startup (Seed)
Booth Number: 807